thrombin generation in plasma, the predictive value of endogenous thrombin generation (ETG)in relation to hypercoagulability and bleedingrisk

There is still much to be learned about the optimal duration of
anticoagulation therapy and predictive risk factors for recurrent thrombosis
and bleeding. At this moment in time screening for thrombophilia gives insight
in the origin of thrombosis only in about 50% of the cases. Currently
prediction of risk for recurrence is based on patient history, clinical
presentation, findings on ultrasonography and laboratory tests. The levels of
factor VIII and D-dimer fragments in the blood are currently used as more or
less predictive laboratory test. Also residual thrombosis is taken into
account. In stead of looking at two seperate coagulation parameters, a more
general assessment of the coagulationsystem can be provided by the endogenous
thrombin generation potential. (ETP) With this test it is possible to establish
within 1 hour whether or not a patient has a prothrombotic tendency. All known
genetic factors such as factor V Leiden mutation, protthrombin mutation,
antithrombin deficiency, protein C and or S deficiency as well as aquired
factors such as lupus anticoagulans and anticardiolipin antibodies can be
detected. Also factors involved in an enhanced bleeding tendency such as factor
VIII deficiency and anti factor VIII antibodies. All these factors can be
observed in their interactive status

Assessing hereditary and aquired determinants of ETP. Evaluating the use of ETP
as predictive stand alone test for recurrent DVT and bleeding complications due
to anticoagulation therapy in comparisson with the current prediction methods.

It is a prospective cohort study in an academic hospital setting

Thete is no risk associated with participation. There is no direct benefit for
the patient.